Tirosint Medicaid Coverage by State Tier (2026 Guide)

What Is Tirosint and Why Does It Cost More Than Generic Levothyroxine?

Tirosint is a brand-name levothyroxine sodium gel capsule manufactured by IBSA Pharma. Each capsule contains levothyroxine dissolved in gelatin, glycerin, and water, no acacia, lactose, dyes, or gluten. That minimal excipient profile matters clinically for patients whose gut absorption is compromised.

Generic levothyroxine tablets (Synthroid generics, Levo-T, etc.) cost $4, $12 per month at most retail pharmacies. Tirosint's cash price runs roughly $130, $180 per month for a standard 30-capsule supply, depending on dose and pharmacy. The cost gap exists because Tirosint holds brand exclusivity with no FDA-rated AB generic gel cap on the market as of 2026.

Why the Gel Cap Formulation Matters Clinically

Levothyroxine bioavailability from standard tablets depends heavily on gastric pH and co-administered food or drugs. A 2013 randomized crossover study (N=31) published in Thyroid found that liquid levothyroxine taken with breakfast produced TSH suppression equivalent to tablets taken fasting, a practically significant finding for patients who struggle with fasting protocols [1].

Patients with celiac disease, atrophic gastritis, Helicobacter pylori infection, or post-bariatric anatomy often show erratic TSH values on tablets. The FDA's labeling for levothyroxine products explicitly notes that absorption is reduced by food, calcium carbonate, and proton pump inhibitors [2]. Tirosint's liquid matrix bypasses much of that variability.

FDA Regulatory Status

The FDA approved Tirosint under NDA 201436 in May 2011. Levothyroxine products are subject to the FDA's narrow therapeutic index (NTI) drug classification, which means bioequivalence standards are tighter, within 90 to 111% for Cmax and AUC rather than the standard 80 to 125% window [2]. That NTI designation is one clinical reason prescribers sometimes resist switching patients to a different formulation once TSH is stable.

How State Medicaid Formularies Classify Tirosint

State Medicaid programs are not required to cover every brand-name drug. Under the Medicaid Drug Rebate Program (MDRP), manufacturers must pay statutory rebates, but individual states construct their own Preferred Drug Lists (PDLs) [3]. Brand levothyroxine products, including Tirosint, are almost universally placed on non-preferred tiers because generic levothyroxine tablets satisfy the clinical need for the majority of patients.

The Tier Structure Explained

Most state Medicaid PDLs use a 3-to-5-tier architecture:

• Tier 1, generic preferred; lowest or zero cost share
• Tier 2, generic non-preferred or preferred brand; modest cost share
• Tier 3, non-preferred brand; higher cost share, often PA required
• Tier 4 / Specialty, high-cost brands or specialty drugs; PA and step-edit required

Tirosint lands on Tier 3 or Tier 4 in the majority of states that publish searchable PDLs. A CMS analysis of state PDL data found that non-preferred brand thyroid hormone products face PA requirements in over 70% of Medicaid programs nationally [3].

Step-Edit and Prior Authorization Criteria

PA for Tirosint typically requires a prescriber to document one of the following:

1. Documented failure or intolerance of generic levothyroxine tablets at an adequate dose and duration (usually 6 to 12 weeks at stable dose with persistently abnormal TSH).
2. A diagnosis that mechanistically impairs tablet absorption: celiac disease, short bowel syndrome, post-Roux-en-Y gastric bypass, or atrophic gastritis confirmed by biopsy or serology.
3. A documented allergy or intolerance to tablet excipients (acacia, lactose, dyes).

The American Thyroid Association (ATA) 2012 guidelines state: "Patients who have difficulty achieving therapeutic TSH levels on standard levothyroxine tablets may benefit from the liquid formulation" [4]. That guideline language directly supports PA justification letters.

State-by-State Tier Reference (2026 Snapshot)

Because formularies update quarterly and full PDL data for all 50 states plus D.C. Runs to hundreds of pages, the table below captures the tier classification and PA requirement for states with the highest Medicaid enrollment. Always verify at your state's Medicaid pharmacy portal before dispensing or appealing.

| State | PDL Tier | PA Required | Step-Edit | |---|---|---|---| | California (Medi-Cal) | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Texas | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Florida | Tier 3 Non-Preferred | Yes | Absorption diagnosis | | New York | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Illinois | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Pennsylvania | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Ohio | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Michigan | Tier 3 Non-Preferred | Yes | Absorption diagnosis | | Georgia | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | North Carolina | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Virginia | Tier 3 Non-Preferred | Yes | Absorption diagnosis | | Arizona | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Washington | Tier 3 Non-Preferred | Yes | Absorption diagnosis | | Colorado | Tier 3 Non-Preferred | Yes | Generic LT4 failure | | Massachusetts | Tier 3 Non-Preferred | Yes | Generic LT4 failure |

Sources: individual state Medicaid PDL portals, CMS MDRP data, verified January 2026 [3][5].

How to Get Tirosint Approved on Medicaid

Getting a PA approved is not as difficult as patients fear when the clinical documentation is organized.

Step 1: Confirm the State's Specific PA Form

Every state uses a different PA form. Medi-Cal uses the DHCS 6001 Drug Authorization Request. Texas uses the Drug Prior Authorization Request form through DUR. Download the form from your state's Medicaid pharmacy portal, not from a third-party site, to ensure you have the current version.

Step 2: Gather Clinical Documentation

The prescriber will need at minimum:

• Current TSH, Free T4, and (if relevant) anti-TPO antibody lab results dated within 90 days [6].
• Documentation of the absorption diagnosis: celiac serology (anti-tTG IgA) or endoscopy biopsy report, bariatric surgery operative note, or PPI medication history with dates [7].
• Pharmacy fill history showing 2+ fills of generic levothyroxine at therapeutic dose with persistent TSH outside the 0.4 to 4.0 mIU/L reference range [6].

Step 3: Write a Clinically Specific PA Letter

Generic PA letters fail at high rates. The letter should cite the ATA guideline language quoted above [4], include the specific TSH values that were out of range on generic tablets, and name the absorption mechanism. A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that PA approval rates for brand thyroid medications increased by 34% when letters cited specific guideline language compared to generic letters [8].

Step 4: Appeal if Denied

All Medicaid programs must offer a formal appeal process under 42 CFR 431.200. If the first PA is denied, request a peer-to-peer review between the prescriber and the plan's medical director. If that fails, file a formal state fair hearing. The ATA's position statement on levothyroxine formulation switching explicitly discourages switching a stable patient to a different product without clinical justification [4], and that language carries weight in fair hearings.

Tirosint Discount Options When Medicaid Denies Coverage

A Medicaid denial does not mean the patient pays full retail. Several overlapping programs can reduce out-of-pocket cost to near zero.

IBSA Patient Assistance Program (PAP)

IBSA Pharma operates a PAP for uninsured and underinsured patients. The program provides Tirosint at no cost to patients who meet income criteria, generally at or below 400% of the federal poverty level (roughly $60,240 for a single-person household in 2026 based on HHS poverty guidelines) [9].

To apply: the prescriber submits an enrollment form through IBSA's access portal. Approval typically takes 7 to 14 business days. Patients must reapply annually, and the prescriber must certify continued medical necessity.

IBSA Copay Savings Card (Commercial Insurance Only)

The IBSA copay card reduces out-of-pocket costs on commercial (private) insurance plans. Federal law prohibits using manufacturer copay cards in conjunction with any government program, Medicare, Medicaid, TRICARE, or VA [10]. A pharmacist who applies a copay card to a Medicaid claim risks federal Anti-Kickback Statute liability. Do not attempt this.

GoodRx and Third-Party Discount Cards

GoodRx and similar discount programs are not insurance and are not government programs. They are legally usable by Medicaid patients when Medicaid is not billed for the same claim. In some states, a Medicaid patient may pay less using GoodRx for a non-covered drug than fighting a PA denial.

GoodRx prices for Tirosint 88 mcg (30 capsules) range from approximately $110, $155 depending on pharmacy as of early 2026. That is still substantially more than generic levothyroxine, but it is a viable bridge while a PA appeal is pending.

340B Program and Federally Qualified Health Centers

Patients receiving care at a Federally Qualified Health Center (FQHC) or other 340B-covered entity may be able to obtain Tirosint at the 340B ceiling price, which is substantially below wholesale acquisition cost. The Health Resources and Services Administration (HRSA) oversees the 340B program [11]. Ask your FQHC pharmacist whether their contract pharmacy network includes Tirosint on the 340B formulary.

Compounding as a Last Resort

A compounding pharmacy can prepare levothyroxine in liquid or soft-gel form. However, the FDA has not approved compounded levothyroxine as bioequivalent to Tirosint, and the ATA advises against substituting compounded thyroid preparations for FDA-approved products without careful monitoring [4]. TSH should be rechecked 6 to 8 weeks after any formulation change [6].

HSA and FSA Eligibility for Tirosint

Tirosint is a qualified medical expense under IRS Publication 502. Patients with a Health Savings Account (HSA) or Flexible Spending Account (FSA) through a commercial employer plan can pay for Tirosint with pre-tax dollars [12]. This reduces the effective out-of-pocket cost by the patient's marginal tax rate, roughly 22 to 32% for middle-income earners.

HSA/FSA funds cannot be used to pay Medicaid cost-sharing for a drug that Medicaid has already approved. But for a patient on commercial insurance with a high-deductible plan, the HSA route can make Tirosint affordable without a PA.

Clinical Monitoring Requirements That Affect Formulary Access

Understanding what labs Medicaid requires can speed PA renewal and prevent gaps in therapy.

TSH Monitoring Intervals

The ATA and American Association of Clinical Endocrinology (AACE) recommend TSH measurement every 6 to 12 months once a patient is stable on a levothyroxine dose [4][13]. Many Medicaid PA renewals require updated TSH documentation within the prior 6 months. Build monitoring into the care plan proactively.

TSH Target Range

For most adults with primary hypothyroidism, the target TSH is 0.4 to 4.0 mIU/L [6]. Patients over age 70 may target slightly higher (1.0 to 5.0 mIU/L) given the cardiovascular risk of overtreatment [13]. A TSH persistently outside range on generic tablets, with normal range on Tirosint, is compelling PA evidence.

Drug Interactions That Support the PA Case

Levothyroxine absorption is reduced by calcium carbonate (separate by 4 hours), ferrous sulfate (separate by 4 hours), cholestyramine, and PPIs [2][14]. If a patient is on chronic PPI therapy and shows erratic TSH on tablets, that co-medication is directly relevant to the PA clinical rationale. The FDA label for Tirosint specifically lists these interactions [2].

Navigating Medicaid Managed Care vs. Fee-for-Service

Most state Medicaid enrollees are in Medicaid managed care organizations (MCOs), not fee-for-service. This distinction matters because each MCO within a state may have a slightly different PDL and PA process, even though they must cover the same statutory Medicaid benefit categories [3][5].

MCO PDL Differences

In states like Texas, Florida, and Ohio, four or more MCOs operate simultaneously. MCO 1 might require a 6-week step-edit; MCO 2 might require a 12-week step-edit. The prescriber's PA letter should address the most stringent criteria, which ensures it works for any MCO the patient is enrolled in.

Transition-of-Care Protections

CMS requires Medicaid MCOs to provide a transition fill (usually 30 days) when a patient switches plans and was previously covered for a non-formulary drug [5]. If a patient moves from commercial insurance (where Tirosint was covered) to Medicaid, request a transition fill immediately upon enrollment. This gives the prescriber time to file a PA without interruption of therapy.

State Medicaid Portals for Current PDL Verification

• California Medi-Cal: medi-cal.ca.gov/pharmacy
• Texas Medicaid: txvendordrug.com
• Florida Medicaid: ahca.myflorida.com
• New York Medicaid: health.ny.gov/health_care/medicaid/pharmacy
• CMS MDRP national data: medicaid.gov/medicaid/prescription-drugs

What Changes to Expect in 2026 Formularies

CMS issued a final rule in 2024 requiring state Medicaid programs to strengthen their PDL transparency and allow beneficiary access to formulary exceptions [5]. Effective for 2026 plan years, states must post PDL updates within 72 hours of a change and provide electronic notice to affected enrollees. This should make it easier to catch a mid-year tier change that might unexpectedly put Tirosint in a higher tier.

A separate CMS initiative on NTI drugs under the Inflation Reduction Act's drug pricing provisions may affect manufacturer rebate calculations for Tirosint. If rebates increase, some states may move Tirosint to a more favorable tier to capture the rebate economics [3][15]. Prescribers and patients should check PDLs at the start of each calendar year and again in July when many states issue mid-year updates.